BioSpace News Archive

Cancer Treatment Centers of America® (CTCA) has released its seventh annual summary of Patient Treatment Results, a comprehensive presentation of treatment outcomes including length of life, quality of life, the patient experience, and patient safety for 11 tumor types.

Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, today introduced AskFirst™, its collaborative program for patients and their families who may benefit from its advances in gene therapy research and potential curative therapies

In 2011, the National Academies Of Sciences, Engineering and Medicine published a report entitled: “Evaluating Systems for the Early Detection of Biological Threats ".

The Centers for Medicare and Medicaid Services (CMS) has assigned an HCPCS Level II code to Omegaven®, the newest parenteral nutrition product introduced in the United States by Fresenius Kabi.

AirAvant Medical, a South Florida-based medical device company, announced that its new Bongo Rx sleep apnea therapy device has been nominated for an Edison Award™.

The REVOCAN phase 1b/2 study, sponsored by Gustave Roussy, will evaluate the effect of AsiDNA™ on the acquired resistance to PARP inhibitor niraparib in 2nd line maintenance treatment of relapsed ovarian cancer

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the company will host a key opinion leader (KOL) event on Wednesday, February 5th, 2020 in New York City.

Verastem, Inc. (Nasdaq: VSTM), (Verastem Oncology or the Company), today announced that its partner CSPC Pharmaceutical Group Limited (HKEx: 1093) (CSPC), a leading pharmaceutical company in China, has dosed the first patient in a pivotal Chinese bridging study evaluating COPIKTRA

Tauriga Sciences, Inc. announced that the United Kingdom’s top alternative well-being magazine, Natural Health Magazine, to feature Tauri-Gum™ in its March 2020 Edition.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to losmapimod, a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor for the treatment of facioscapulohumeral muscular dystrophy (FSHD)